Combination of norepinephrine reuptake inhibitor and a cannabinoid for use in treating sleep apnea
AssigneeApnimed, Inc. (Delaware)
InventorsLawrence G. MILLER, Luigi TARANTO-MONTEMURRO, Ronald FARKAS, David P. WHITE
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions comprising a norepinephrine reuptake inhibitor (NRI) and a cannabinoid and optionally a muscarinic receptor antagonist (MRA) and/or carbonic anhydrase inhibitor (CAI) and methods of treating sleep apnea are described herein.
Claims75
A method of treating a subject having a condition associated with pharyngeal airway collapse, the method comprising administering to a subject in need thereof an effective amount of (i) a norepinephrine reuptake inhibitor (NRI) and (ii) a cannabinoid.
A pharmaceutical composition comprising (i) a norepinephrine reuptake inhibitor (NRI) and (ii) a cannabinoid, in a pharmaceutically acceptable carrier.
A kit comprising (i) a norepinephrine reuptake inhibitor (NRI) and (ii) a cannabinoid, and optionally (iii) a muscarinic receptor antagonist (MRA) and/or carbonic anhydrase inhibitor (CAI).
A norepinephrine reuptake inhibitor (NRI) and a cannabinoid, and optionally a muscarinic receptor antagonist (MRA) and/or carbonic anhydrase inhibitor (CAI), for use in treating a subject having a condition associated with pharyngeal airway collapse.
A therapeutic combination of (i) a norepinephrine reuptake inhibitor (NRI) and (ii) a cannabinoid, and optionally (iii) a muscarinic receptor antagonist (MRA) and/or carbonic anhydrase inhibitor (CAI), for use in treating a subject having a condition associated with pharyngeal airway collapse.
Dependencies are inferred from the claim text.